Wedbush Reiterates Outperform on Inozyme Pharma, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $15 price target.
July 26, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $15 price target.
The reiteration of an Outperform rating and the maintenance of a $15 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100